Последние новости

Реклама

В.В СКЛЯРЕВИЧ. Антибактериальные лекарственые средства. Методы стандартизации препаратов. Раздел 2

В.В СКЛЯРЕВИЧ. Антибактериальные лекарственые средства. Методы стандартизации препаратов. Страница 156

20. Kim R. B. Organic anion-transporting polypeptide (OATP) transporter family and drug disposition // Eur. J. Clin. Invest. — 2003. — Vol. 33, Suppl. 2. - P. 1-5.

21. MacKichan J. J. Protein binding drug displacement interactions fact or fiction? // Clin. Pharmacokinet. - 1989. - Vol. 16. — P. 65-73.

22. Michalets E. L. Update: clinically significant cytochrome P-450 drug interactions // Pharmacotherapy. — 1998. — Vol. 18. — P. 84—112.

23. Niki Y., Hashiguchi K., Okimoto N., Soejima R. Quinolone antimicrobial agents and theophylline // Chest. — 1992. — Vol. 101. — P. 881.

24. Lumholtz B., Siersbaek-Nielsen K., Skovsted L. et al Sulfamethizole-in- duced inhibition of diphenylhydantoin, tolbutamide, and warfarin metabolism 11 Clin. Pharmacol. Ther. — 1975. - Vol. 17. — P. 731-734.

25. Metabolic drug interactions / Eds Rene H. Levy et al.— Philadelphia,

2000.

26. Page C., Curtis M., Sutter M. et al Pharmacology. — Edinburgh: Mos- by, 2002.

27. Periti P., Mazzei T., Mini E., Novelli A. Pharmacokinetic drug interactions of macrolides // Clin. Pharmacokinet. — 1992. — Vol. 23. — P. 106-131.

28. Pharmacogenomics / Ed. by M. A. Rothstein. — Edinburgh, 2003.

29. Quinn D. /., Day R. O. Drug interactions of clinical importance: an updated guide // Drug. Saf. - 1995. - Vol. 12 (6). - P. 393-452.

30. Rang H. P., Dale M. M., Ritter J. M., Moore P. K. Pharmacology. — Edinburgh, 2003.

31 .Rolan P. E. Plasma protein binding displacement interactions — why are they still regarded as clinically important? // Br. J. Clin. Pharmacol. - 1994. - Vol. 37. - P. 125-128.

32. Sansom L. N.f Evans A. M. What is the true clinical significance of plasma protein binding displacement interactions? // Drug. Saf. — 1995. - Vol. 12. - P. 227-233.